Page 44 | Certara

Publication

Model-informed drug discovery and development approaches to inform clinical trial design and regulatory decisions: A primer for the MENA region

The integration of MID3 offers a transformative opportunity for the MENA region to advance pharmaceutical…

CertaraJanuary 14, 2025

Press Coverage

What 2025 could bring for psychedelic use in healthcare

Explore the evolving landscape of psychedelic medicine, featuring updates from key players and insights on…

CertaraJanuary 13, 2025

Fact Sheet

Simcyp® In Vitro Data Analysis (SIVA) Toolkit

CertaraJanuary 10, 2025

On-Demand Webinar

Unlock Global Regulatory Success: Overcoming Early Drug Development Challenges [APAC Webinar]

Navigating early drug development is critical to ensuring the long-term success of therapeutic candidates. This…

CertaraJanuary 10, 2025

Blog

Why FDA’s omaveloxolone approval for Friedreich’s ataxia matters

January 10, 2025 Friedreich’s Ataxia (FA) is a rare, genetic, and progressive neurodegenerative disorder. A…

CertaraJanuary 10, 2025

Announcement

Certara Appoints New Head of Biometrics, Data Science, and Access

January 10, 2025 RADNOR, PA. – January 10, 2025 – Certara, Inc. (Nasdaq: CERT), a global…

CertaraJanuary 10, 2025

On-Demand Webinar

Solving Drug Development Challenges with Model-Based Meta-Analysis (MBMA)

In this on-demand webinar, "MBMA: Optimizing Drug Development with Aggregate Clinical Trial Data and Predictive…

CertaraJanuary 9, 2025

Publication

INTERCEPT-AD, a phase 1 study of intravenous sabirnetug in participants with mild cognitive impairment or mild dementia due to Alzheimer’s disease

The Phase 1 INTERCEPT-AD study evaluated sabirnetug (ACU193), a monoclonal antibody targeting amyloid-beta oligomers (AβOs),…

CertaraJanuary 8, 2025

Case Study

Helping Sponsor Meet EMA Policy 0070 Requirements

The European Medicines Agency’s Policy on the Publication of Clinical Data for Medicinal Products for…

CertaraJanuary 7, 2025

On-Demand Webinar

AI-powered regulatory writing software – Frequently asked questions by Japanese customers [Japanese Webinar]

Faced with more and more complex clinical research than ever before, regulatory writers are facing…

CertaraJanuary 6, 2025

Model-informed drug discovery and development approaches to inform clinical trial design and regulatory decisions: A primer for the MENA region

What 2025 could bring for psychedelic use in healthcare

Simcyp® In Vitro Data Analysis (SIVA) Toolkit

Unlock Global Regulatory Success: Overcoming Early Drug Development Challenges [APAC Webinar]

Why FDA’s omaveloxolone approval for Friedreich’s ataxia matters

Certara Appoints New Head of Biometrics, Data Science, and Access

Solving Drug Development Challenges with Model-Based Meta-Analysis (MBMA)

INTERCEPT-AD, a phase 1 study of intravenous sabirnetug in participants with mild cognitive impairment or mild dementia due to Alzheimer’s disease

Helping Sponsor Meet EMA Policy 0070 Requirements

AI-powered regulatory writing software – Frequently asked questions by Japanese customers [Japanese Webinar]

Newsletter sign up

Quick links

Solutions

Contact